CLINICAL ROLE -
Emerging Therapies & Strategies in Schizophrenia
Watch
Improving Resistance to Use LAI Therapy in Schizophrenia
LAI Antipsychotics in Schizophrenia: Clinician's Role
LAI Antipsychotics in Schizophrenia: Tolerability
LAI Antipsychotics: Treatment Selection in Schizophrenia
LAI Antipsychotics: Establishing a Treatment Plan
Underutilization of LAI Antipsychotics in Schizophrenia
Effects of Schizophrenia Relapse on Hospitalization
Preventing Relapses in Schizophrenia
Consequences of Relapses in Schizophrenia
Predictors of Relapse in Schizophrenia
Current Challenges in the Treatment of Schizophrenia
Optimal Treatment of Schizophrenia: Take-Home Messages
Overcoming Obstacles to LAIs in Schizophrenia Management
Schizophrenia: Switching to a Long-Acting Injectable
Benefit of Long Acting Injectables in Schizophrenia
Adherence to Oral Agents in Schizophrenia Management
Schizophrenia: Understanding the Impact of Adherence
Schizophrenia: Consequences of Multiple Relapses
Importance of Relapse Prevention in Schizophrenia
Unmet Needs and Challenges in Managing Schizophrenia
Partnership Designed to Improve Medication Adherence Among Patients with Type 2 Diabetes
The program launched by the Baltimore-based organizations is the first of its kind to leverage video technology and a public health practice known as Directly Observed Therapy, or DOT.
Read More
In the Age of the Drone, Are You a Dinosaur?
In 2019, you can change your destiny, or you can maintain the status quo. You have a choice: become a drone or remain a dinosaur.
Treatment for Chronic Idiopathic Constipation Receives FDA Approval
Prucalopride (Motegrity, Shire) is the only serotonin-4 receptor agonist approved for adults with Chronic Idiopathic Constipation.
FDA Approves New Drug for Chronic Idiopathic Constipation
Prucalopride (Motegrity, Shire) is the only serotonin-4 receptor agonist approved for adults with chronic idiopathic constipation.
Flu Vaccination Reminders Prove Effective for Patients With Diabetes
Influenza vaccinations among patients with diabetes rose by 20% when they were notified about scheduling their flu shot, according to a new study.
FDA OKs Chronic Idiopathic Constipation Treatment
Officials with the FDA have approved prucalopride (Motegrity, Shire) for the treatment of chronic idiopathic constipation.
The Specialty Journey: Beauty Lies in the Eyes of the Patient
Specialty pharmacy stakeholders must strike a delicate balance between cost concerns and health outcomes, while keeping the patient at the center.
Trending News Today: Poll Finds 1 in 3 Americans Delayed Medical Treatment Due to Cost
Top news of the day across the health care landscape.
Trending News Today: Study Shows Taltz Superior to Humira in Active Psoriatic Arthritis
